New Alzheimer's Injection Halves Cognitive Decline in Phase Two Trial

Key Takeaways
- Diranersen is a twice-yearly injection administered via lumbar puncture into spinal fluid.
- The phase two trial enrolled 416 patients with early-stage Alzheimer's disease across multiple global centers.
- Patients receiving the 60mg dose experienced 54 percent less memory and thinking decline compared to the placebo group.
OPA WIRE, Nov 19 (OPA) — A phase two trial involving 416 patients with early Alzheimer's disease found that diranersen reduced memory and thinking decline by 54 percent at the lowest dose of 60mg every six months compared to a placebo. The treatment, administered via lumbar puncture into spinal fluid, also showed a 38 percent reduced decline in measures tracking everyday activities. Researchers noted the drug successfully reduced levels of tau, a harmful protein linked to brain cell death.
Co-author Professor Jeffrey Cummings told the Clinical Trials on Alzheimer's Disease conference in Boston that researchers effectively reversed Alzheimer pathology by removing tau tangles. Harvard Medical School neurology professor Reisa Sperling described the findings as thrilling. The trial was funded by Biogen, which is developing the medication alongside Ionis Pharmaceuticals across multiple global centers.
Independent experts cautioned that the findings require confirmation in larger phase three trials before definitive conclusions can be drawn. Professor Rob Howard of University College London noted that while the underlying science is clever, premature claims should be avoided until broader data is available. Common side effects observed during the trial included injection site pain, headaches, and confusion, particularly at higher doses.
Patients in the UK are currently being recruited for upcoming phase three trials slated to begin in spring through the National Institute for Health and Care Research. Trial locations are scheduled for London, Manchester, Birmingham, and Oxford. The new findings distinguish diranersen from other treatments like lecanemab and donanemab, which target amyloid plaques rather than tau pathology inside brain cells.
Subscribe to the Global Briefing
Receive our flagship executive dispatch every morning. Essential geopolitical analysis, financial benchmarks, and breaking world events delivered to your inbox.
Mohammad Karamali
Verified Wire ContributorSenior correspondent covering geopolitics, regional developments, and strategic international affairs for OPA News (Optimum Public Affairs).
Related Stories & Follow-ups
Editorial WireReader Discussion
Leave a Comment
0 Comments
Owner
Editorial Oversight & Machine-Assisted Reporting
Human-in-the-Loop VerifiedEditorial Oversight & Machine-Assisted Reporting: This dispatch was synthesized and localized via OPA automated intelligence under continuous human editorial supervision.
Wire Source
This report was synthesized from Daily Mail under journalistic fair use.



